PhotoCure reports positive Phase III data

Photocure (OSE:PHO) said data from a 120-patient Phase III trial of PHO's Metvix photodynamic dynamic therapy (PDT) to treat primary superficial basal cell carcinoma (BCC) showed more than 90 percent ...